NCT05335044

Study to Evaluate the Safety and Pharmacokinetics of CKD-331

An Open-label, Randomized, Single-dose, 2-sequence, 4-period, Cross-over, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of CKD-331 in Healthy Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 47 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

Phase 1 study to evaluate the safety and pharmacokinetics of CKD-331 in healthy adult volunteers

Detailed description

An open-label, randomized, single-dose, 2-sequence, 4-period, cross-over, phase 1 study to evaluate the safety and pharmacokinetics of CKD-331 in healthy adult volunteers

Conditions

• Hypertension and Dyslipidemia

Interventions

Type	Name	Description
DRUG	CKD-331	QD, PO
DRUG	EX5619	QD, PO

Timeline

• Start date: 2022-05-31
• Primary completion: 2022-06-23
• Completion: 2022-07-12
• First posted: 2022-04-19
• Last updated: 2023-06-09

Locations

1 site across 1 country: South Korea